Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy

Key Points

• Acoramidis reduced the composite outcome of all-cause mortality and cardiovascular hospitalization compared to placebo.
• The early effect was primarily due to a reduction in cardiovascular hospitalizations among participants.
• This analysis focuses on transthyretin amyloid cardiomyopathy, a serious heart condition.
• These findings may indicate a promising intervention for managing ATTR-CM and improving patient outcomes.